CA2366750C - (e)-styryl sulfone anticancer agents - Google Patents

(e)-styryl sulfone anticancer agents Download PDF

Info

Publication number
CA2366750C
CA2366750C CA2366750A CA2366750A CA2366750C CA 2366750 C CA2366750 C CA 2366750C CA 2366750 A CA2366750 A CA 2366750A CA 2366750 A CA2366750 A CA 2366750A CA 2366750 C CA2366750 C CA 2366750C
Authority
CA
Canada
Prior art keywords
hydrogen
fluoro
chloro
bromo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2366750A
Other languages
English (en)
French (fr)
Other versions
CA2366750A1 (en
Inventor
E. Premkumar Reddy
M. V. Ramana Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University
Original Assignee
Temple University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University filed Critical Temple University
Publication of CA2366750A1 publication Critical patent/CA2366750A1/en
Application granted granted Critical
Publication of CA2366750C publication Critical patent/CA2366750C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2366750A 1999-04-02 2000-03-31 (e)-styryl sulfone anticancer agents Expired - Fee Related CA2366750C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12768399P 1999-04-02 1999-04-02
US14397599P 1999-07-15 1999-07-15
US60/127,683 1999-07-15
US60/143,975 1999-07-15
PCT/US2000/008565 WO2000059495A1 (en) 1999-04-02 2000-03-31 (e)-styryl sulfone anticancer agents

Publications (2)

Publication Number Publication Date
CA2366750A1 CA2366750A1 (en) 2000-10-12
CA2366750C true CA2366750C (en) 2010-06-01

Family

ID=26825868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366750A Expired - Fee Related CA2366750C (en) 1999-04-02 2000-03-31 (e)-styryl sulfone anticancer agents

Country Status (7)

Country Link
EP (1) EP1173160B1 (enExample)
JP (1) JP4596651B2 (enExample)
AT (1) ATE298234T1 (enExample)
AU (1) AU774738B2 (enExample)
CA (1) CA2366750C (enExample)
DE (1) DE60020954T2 (enExample)
WO (1) WO2000059495A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388343A1 (en) * 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
WO2002067913A1 (en) 2001-02-27 2002-09-06 Temple University-Of The Commonwealth System Of Higher Education (z)-styrylbenzylsulfones and pharmaceutical uses thereof
US6667346B2 (en) 2001-02-28 2003-12-23 Temple University - Of The Commonwealth System Of Higher Education Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
US8664272B2 (en) * 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3463774A (en) * 1963-03-18 1969-08-26 Hoffmann La Roche Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines
JPH0641054A (ja) * 1992-07-27 1994-02-15 Mitsubishi Petrochem Co Ltd スチリルスルホン誘導体、それを有効成分とする殺菌剤およびその製造方法
TR199801495T2 (xx) * 1995-06-07 1998-09-21 Eli Lilly And Company Vinil s�lfoksitler ve sentezlenmeleri i�in bir i�lem.
ATE284386T1 (de) * 1997-10-03 2004-12-15 Univ Temple Styrolsulfone als antikrebsmittel
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
WO2000059494A1 (en) * 1999-04-02 2000-10-12 Temple University- Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
IL149064A0 (en) * 1999-10-12 2002-11-10 Univ Temple Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Also Published As

Publication number Publication date
AU774738B2 (en) 2004-07-08
EP1173160B1 (en) 2005-06-22
CA2366750A1 (en) 2000-10-12
ATE298234T1 (de) 2005-07-15
EP1173160A4 (en) 2003-02-19
DE60020954T2 (de) 2006-05-11
JP4596651B2 (ja) 2010-12-08
AU4185300A (en) 2000-10-23
WO2000059495A1 (en) 2000-10-12
JP2002541102A (ja) 2002-12-03
EP1173160A1 (en) 2002-01-23
DE60020954D1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
US6787667B2 (en) (E)-styryl sulfone anticancer agents
US6642410B2 (en) Substituted benzylthioacetic acids and esters
AU2001251615A1 (en) Substituted styryl benzylsulfones for treating proliferative disorders
CA2368653C (en) Z-styryl sulfone anticancer agents
US6548553B2 (en) Styryl sulfone anticancer agents
EP1173160B1 (en) (e)-styryl sulfone anticancer agents
AU2001251614B2 (en) Alpha,beta-unsaturated sulfones for treating proliferative disorders
AU2001251614A1 (en) Alpha,beta-unsaturated sulfones for treating proliferative disorders
CA2424884C (en) Substituted (e)-styryl benzylsulfones for treating proliferative disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180403